牛津,阿斯利康疫苗在老年人中的强烈反应在审查中得到证实

2020-11-19 20:03

Oxford, AstraZeneca Vaccine’s Strong Response in Elderly Confirmed in Review zls世界播

牛津,阿斯利康疫苗在老年人中的强烈反应在审查中得到证实zls世界播


暂无zls世界播

A scientist working in August at a laboratory plant in Garin, Argentina, where a coronavirus vaccine developed by the University of Oxford and AstraZeneca will be produced for Latin America. zls世界播

今年8月,一名科学家在阿根廷加林的一家实验室工作,牛津大学和阿斯利康公司(AstraZeneca)将在那里为拉丁美洲生产冠状病毒疫苗zls世界播


LONDON—A Covid-19 vaccine being developed by the University of Oxford and AstraZeneca PLC showed promising immune responses in elderly and older adults, with fewer serious side effects than in younger volunteers, according to a just-published interim analysis previewed in late October. zls世界播

伦敦-牛津大学(University Of Oxford)和阿斯利康(AstraZeneca PLC)正在开发的新冠肺炎疫苗在老年人和老年人中显示出良好的免疫反应,严重副作用比年轻志愿者少,10月底预览的一份中期分析报告显示。zls世界播


The data from that preview have now been peer reviewed. The results were published Thursday in the Lancet medical journal, providing a stamp of approval for the earlier findings. The data were based on earlier, Phase Two human trials of the vaccine. zls世界播

该预览版的数据现已经过同行评审。这项研究结果于周四发表在《柳叶刀》医学杂志上,为之前的研究结果提供了认可。这些数据是基于早些时候疫苗的第二阶段人体试验。zls世界播


AstraZeneca and Oxford have yet to release later-stage, or Phase Three, trial data demonstrating the vaccine’s overall efficacy in fighting Covid-19. Those trials continue. zls世界播

阿斯利康(AstraZeneca)和牛津大学(Oxford)尚未公布后期或第三阶段的试验数据,证明该疫苗在对抗新冠肺炎方面的总体效果。这些审判仍在继续。zls世界播


Drugmakers of two rival vaccine candidates—one from Pfizer Inc. and Germany’s BioNTech SE and another from Moderna Inc. —have each disclosed efficacy rates of more than 90%, higher than many had expected from vaccines developed so quickly. The vaccines’ full safety data hasn’t yet been published. zls世界播

两个竞争对手候选疫苗的制药商--其中一个来自辉瑞公司(Pfizer Inc.)。德国的BioNTech SE和另一家来自现代公司的公司。-每一家公司都披露了90%以上的有效率,高于许多人对如此快速开发的疫苗的预期。疫苗的全部安全性数据尚未公布。zls世界播


People involved in the Oxford-AstraZeneca vaccine have said they expect their efficacy data, from ongoing late-stage trials, in the coming weeks. Unlike the Pfizer and Moderna programs, which rely on a new vaccine technology called messenger RNA, the vaccine developed by AstraZeneca and Oxford represents a more traditional approach. zls世界播

参与牛津-阿斯利康(Oxford-AstraZeneca)疫苗研发的人士表示,他们预计未来几周将公布正在进行的后期试验的疗效数据。与辉瑞(Pfizer)和摩登那(Modern Na)项目不同,后者依赖一种名为信使RNA(Messenger RNA)的新疫苗技术,而阿斯利康(AstraZeneca)和牛津大学(Oxford)开发的疫苗代表了一种更。zls世界播


AstraZeneca has committed to making the vaccine at greater volumes across a wider geographic footprint than its Western peers. It has also promised to deliver doses at no profit during the pandemic, and continuing afterward for poorer countries. All that has heightened anticipation of clinical results for the AstraZeneca vaccine, with hopes it can complement rollouts of other shots in parts of the world that might not have immediate access to Pfizer’s and Moderna’s shots. zls世界播

阿斯利康(AstraZeneca)承诺在比西方同行更广泛的地理区域内生产更大数量的疫苗。它还承诺在大流行期间免费提供疫苗,并在疫情爆发后继续为较贫穷的国家提供疫苗。所有这些都提高了人们对阿斯利康(AstraZeneca)疫苗临床效果的预期,希望它能补充世界上一些可能无法立即获得辉瑞(Pfizer)和现代(Modern Na)疫苗的地区推出的其他疫苗。zls世界播


暂无zls世界播

Health experts say having a vaccine is just one front in a two-front battle against Covid-19. The other is effective treatments for those who are already sick with the disease. WSJ breaks down the three most promising types in development. Photo Illustration: Jacob Reynolds/WSJ. zls世界播

卫生专家表示,接种疫苗只是对抗新冠肺炎的两条战线中的一条战线。另一种是对那些已经患有这种疾病的人进行有效的治疗。《华尔街日报》分析了发展中最有前途的三种类型。图片插图:雅各布·雷诺兹/《华尔街日报》zls世界播


The data describing the vaccine’s effect on older people has also taken on outsize importance, since this group is especially vulnerable to serious illness or death from the virus. zls世界播

描述疫苗对老年人影响的数据也变得格外重要,因为这一群体特别容易患重病或死于病毒。zls世界播


In the peer-reviewed study of the vaccine, healthy adults aged 56 and older showed similar positive immune responses to younger trial participants. The oldest adults involved—with an average age of 73-74 years—showed milder adverse reactions, according to early results published Thursday. zls世界播

在疫苗的同行评议研究中,56岁及以上的健康成年人对年轻的试验参与者表现出类似的阳性免疫反应。根据周四公布的早期结果,受试者中年龄最大的成年人-平均年龄在73-74岁-表现出较轻的不良反应。zls世界播


Governments are expected to give priority to older adults in rollouts of vaccines, which could start in limited quantities before the end of this year. Scientists have said they expect different age groups to react differently to different vaccines—a big reason why they expect multiple vaccines to be necessary to protect all ages in the coming months and years. zls世界播

预计各国政府将在推出疫苗时优先考虑老年人,疫苗可能在今年年底前限量开始。科学家们表示,他们预计不同年龄段的人对不同的疫苗会有不同的反应-这是他们预计在未来几个月和几年里有必要接种多种疫苗来保护所有年龄段的一大原因。zls世界播


The Oxford vaccine spurred trial participants’ immune systems to find and attack cells infected with the virus, and following a second, booster shot was effective in attacking the virus in the bloodstream, according to the interim results. Those positive outcomes were present in all age groups given low and standard doses. Some participants received just one shot, while others got a booster after 28 days. The early-stage study involved 560 healthy adults, including 240 people older than 70 years. Most were white nonsmokers. zls世界播

根据中期结果,牛津疫苗刺激试验参与者的免疫系统找到并攻击感染病毒的细胞,在第二次增强注射后,有效地攻击了血液中的病毒。在给予低剂量和标准剂量的所有年龄组中,这些阳性结果都存在。一些参与者只接受了一次注射,而另一些参与者在28天后接受了强化注射。这项早期研究涉及560名健康成年人,其中包括240名70岁以上的人。大多数是不吸烟的白人。zls世界播


The continuing late-stage trials of the vaccine will show broader results for safety and efficacy, including in older adults with underlying health conditions, and from a wider range of backgrounds, countries and ethnicities of all ages, researchers said. zls世界播

研究人员表示,继续进行的疫苗后期试验将显示出更广泛的安全性和有效性结果,包括在有潜在健康状况的老年人身上,以及来自更广泛的背景、国家和所有年龄段的种族。zls世界播


“Immune responses from vaccines are often lessened in older adults because the immune system gradually deteriorates with age, which also leaves older adults more susceptible to infections,” said Andrew Pollard, an Oxford professor who is the lead author of the study. zls世界播

该研究的主要作者、牛津大学教授安德鲁·波拉德(Andrew Pollard)说:“老年人对疫苗的免疫反应通常会减弱,因为免疫系统会随着年龄的增长逐渐恶化,这也会让老年人更容易受到感染。”zls世界播


The most common side effects were pain at the injection site, fatigue, headache, feverishness and muscle pain. Fewer people aged 70 or over experienced those temporary symptoms, compared with younger trial participants, researchers said. zls世界播

最常见的副作用是注射部位疼痛、疲劳、头痛、发烧和肌肉疼痛。研究人员说,与年轻的试验参与者相比,70岁或70岁以上的人经历这些暂时性症状的人更少。zls世界播

© 2016 世界播 www.shijiebobao.com 中国互联网举报中心 京ICP证140141号 鄂ICP备18018000号-1
违法和不良信息举报: